- Trial phase
- Approved (FDA, NDA 219407)
- Time to market
- Already approved and on the U.S. market, FDA approval Aug 21, 2025 (NDA 219407, New Molecular Entity).
- Why 3/10
- No scheduled regulatory decision for DAWNZERA in the next ~12 months: its FDA approval (Aug 21, 2025) already passed with a flat stock reaction (-0.28% 1-day, -1.49% 5-day), so this is an approved, commercial-stage asset inside a multi-program company whose dated 2026 binaries (zilganersen PDUFA Sep 22, 2026; bepirovirsen PDUFA Oct 26, 2026) belong to other drugs, capping impactScore at 3-5 territory for a marketed product.
DAWNZERA itself is not a near-term trading catalyst, the binary event (FDA approval) already happened in Aug 2025 and did not move IONS. For a non-medical investor, Dawnzera matters as part of Ionis' commercial portfolio story; the next hard price drivers for IONS stock are the zilganersen PDUFA (Sep 22, 2026) and bepirovirsen PDUFA (Oct 26, 2026). Watch quarterly earnings disclosures (10-Q filed Jul 29, 2026) for Dawnzera launch metrics, and note the rising FINRA short position (~12.13% of est. shares outstanding at the 7/15/2026 settlement) and July insider sales as sentiment headwinds.
Price Chart
Executive Summary
DAWNZERA (generic: donidalorsen, code IONIS-PKK-LRx) is Ionis Pharmaceuticals' wholly-owned antisense-oligonucleotide preventive for hereditary angioedema (HAE), approved by the FDA on Aug 21, 2025 as a New Molecular Entity (NDA 219407) in an autoinjector presentation; its supporting Phase 2 extension study in HAE is complete. The approval was a non-event for the stock (IONS -0.28% 1-day, -1.49% 5-day around the date). Dawnzera is one of several marketed Ionis drugs, the company's dated 2026 catalysts are other programs (zilganersen PDUFA Sep 22, 2026; bepirovirsen PDUFA Oct 26, 2026).
How It Works
Dawnzera is an antisense drug: a short piece of synthetic genetic material that reduces the body's production of prekallikrein (PKK), a liver-made protein involved in the pathway that drives the sudden swelling attacks of hereditary angioedema (HAE). By keeping PKK levels low, it is meant to prevent attacks rather than treat them after they start. It is given by subcutaneous injection via an autoinjector (per the approved product name), making it a home-use prophylactic.
Trial Status
FDA-approved Aug 21, 2025 as a Type 1 New Molecular Entity (donidalorsen) per the OPENFDA catalyst record. Supporting data include a completed Phase 2 extension study of donidalorsen (IONIS-PKK-LRx) in hereditary angioedema (NCT04307381, completed Jan 2025, has results); the product is now in commercial launch in the autoinjector presentation.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for DAWNZERA itself (already approved, commercial stage)
- Company-level, other drugs: zilganersen PDUFA action date Sep 22, 2026 (Alexander disease)
- Company-level, other drugs: bepirovirsen NDA Priority Review PDUFA date Oct 26, 2026 (chronic hepatitis B)
- Quarterly earnings (next 10-Q / earnings release) for Dawnzera launch revenue commentary
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IONIS PHARMACEUTICALS INC 8-K IONS ·Originating report